Medicaid and CHIP State Plan, Waiver, and Program Submissions

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in program monitoring of Medicaid Section 1115 Substance Use Disorder Demonstrations. This mandatory information collection (42 CFR § 431.428) will be used to support more efficient, timely and accurate review of states' SUD 1115 demonstrations monitoring reports submissions to support consistency of monitoring and evaluation of SUD 1115 Demonstrations, increase in reporting accuracy, and reduce timeframes required for monitoring and evaluation. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is **0938-1148** (CMS-10398 #57)." If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

1. Title Page for the State's SUD Demonstration or SUD Components of Broader Demonstration

The state should complete this Transmittal Title Page at the beginning of a demonstration and submit as the title page of all SUD Monitoring Reports. The content of this transmittal table should stay consistent over time.

| State | Vermont |
|---------------------------|---|
| | |
| Demonstration Name | Global Commitment to Health 1115 Demonstration |
| | |
| | June 28, 2022 |
| Approval Date | |
| | July 1, 2022, to December 31, 2027 |
| Approval Period | |
| | 1. Increase rates of identification, initiation, and engagement in |
| | treatment. |
| | 2. Improve access to care for physical health conditions among beneficiaries. |
| SUD (or if broader | 3. Increase adherence to and retention in treatment. |
| demonstration, then SUD | 4. Reduce overdose deaths, particularly those due to opioids. |
| Related) Demonstration | 5. Reduce utilization of emergency department and inpatient hospital |
| Goals and Objectives | settings for treatment where the utilization is preventable or |
| ď | medically inappropriate through improved access to other |
| | continuum of care services. |
| | 6. Reduce readmissions to the same or higher level of care where the |
| | readmission is preventable or medically inappropriate. |

2. Executive Summary

The executive summary should be reported in the fillable box below. This executive summary is intended for summary level information only. The recommended word count is 500 words or less.

The Division of Substance Use Programs (DSU) is executing the work included in the implementation roadmap for the expanded eligibility group for people with a SUD diagnosis (referred to as "SUD CIT" - Community Intervention and Treatment) and continues executing the work included in the implementation roadmaps that would make recovery services and supports, and withdrawal management services Medicaid eligible. These projects are currently scheduled for 2025 implementation.

DSU representatives have been engaged in the discussions and process development to account for the Mid-Point Assessment.

The Substance Use Disorder Treatment Standards, revised January 1, 2024, are being used to certify Preferred Providers and is available at:

 $\underline{https://www.healthvermont.gov/alcohol-drugs/professionals/treatment-provider-certification}$

The Compliance Assessment Tool (CAT) is used during site visits to determine a Preferred Provider's level of certification compliance by providing transparency about the Preferred Provider's status; highlighting areas that require action or emphasis; and evaluating the level and type of technical assistance need. The CAT has been used two times between July 1, 2024, and September 30, 2024, at treatment provider locations.

DSU and the DVHA Payment Reform team received approval from CMS regarding the incentives for a value-based payment model for residential programs to align with its All-Payer Model Agreement with CMS.

From 7/1/2024-9/30/2024, VT Helplink, DSU's centralized intake and resource center, received 295 calls and 7,942 website visits. Work to implement text message functionality has been completed. Vermonters can now text "LINK" to the VT Helplink phone number to initiate a call with a Screening & Information Specialist. Vermonters are now able to access VT Helplink online, by telephone call, or by text message. Work continues on transitioning the Vermont Alcohol and Drug Information Clearinghouse ("Clearinghouse") under the VT Helplink service. The Clearinghouse will allow Vermonters to order free substance use and mental health materials and access online/digital materials through VT Helplink. This service is expected to be developed and implemented before the end of the year.

The Substance Misuse Prevention Oversight and Advisory Council (SMPC) was established within the Vermont Department of Health and addresses all substances of misuse. The SMPC has three goals: 1) Increase protective factors and build resilience and feelings of connectedness in Vermont communities, across all ages, cultures, and socioeconomic conditions; 2) Decrease risk factors for substance use in Vermont for individuals of all ages, cultures, and socioeconomic conditions; 3) Increase efficiency and collaboration on prevention efforts across all state, public, and private entities, through a consolidated and holistic approach to prevention that is sustainable, scalable, and equitable. The SMPC submitted their 2024 Annual Report to the Vermont General Assembly. Additional information on the SMPC can be found at: www.healthvermont.gov/SMPC

The Recovery Coaches in the Emergency Department Program is fully implemented in all 14 emergency departments in the state. Over 800 individuals have been served through this program between 10/1/23-6/30/24.

Vermont's assembled Part 2 Data Governance Group has successfully incorporated SUD data into the Vermont Health Information Exchange (VHIE) for a select group of providers. The data is going into a repository but is not yet accessible for use. Other SUD providers will be included over time, although a timeline has not yet been established.

3. Narrative Information on Implementation, by Reporting Topic

| Prompts | Demonstration year (DY) and quarter first reported | Related metric (if any) | Summary |
|--|--|--|--|
| 1.2 Assessment of Need and 1.2.1 Metric Trends | Qualification for S | UD Services | |
| Discuss any relevant trends that the data shows related to assessment of need and qualification for SUD services. At a minimum, changes (+ or -) greater than two percent should be described. | | | |
| described. | DY20 Q3 | 3 Number of beneficiaries who receive MAT or a SUD-related treatment service with an associated SUD diagnosis during the measurement period and/or in the 11 months before the measurement period (+21.7%) | For this period, we may be seeing people who disengaged with services during the pandemic now coming back into treatment or those who increased substance use during the pandemic seeking care. |
| | DY20 Q3 Annual | 22 Percentage of adults 18 years of age and older with pharmacotherapy for OUD who have at least 180 days of continuous treatment (+2.4%) | More people are receiving pharmacotherapy, and more are staying on it. It may be due to greater stability after the COVID interruptions in care. Note: We have historically seen underrepresented rates due to provider claims reporting practices. We developed some code to identify improperly reported claims, which are integrated into this year's report. In the process, we found that the code to produce this |

| | | | measure did not run correctly last year so we reran the 2022 data for a direct comparison to 2023. | | |
|--|---|--------------------|--|--|--|
| | | | 2022 data for a direct comparison to 2023. | | |
| ☐ The state has no metrics tr | ☐ The state has no metrics trends to report for this reporting topic. | | | | |
| 1.2.2 Implementation Upda | • | s reporting topic. | | | |
| Compared to the | ie – | | | | |
| demonstration design | | | | | |
| details outlined in the STCs | | | | | |
| and implementation plan, | | | | | |
| have there been any | | | | | |
| changes or does the state | | | | | |
| expect to make any changes | | | | | |
| to: A) the target | | | | | |
| population(s) of the | | | | | |
| demonstration? B) the | | | | | |
| clinical criteria (e.g., SUD | | | | | |
| diagnoses) that qualify a | | | | | |
| beneficiary for the | | | | | |
| demonstration? | | | | | |
| Are there any other | | | | | |
| anticipated program | | | | | |
| changes that may impact | | | | | |
| metrics related to | | | | | |
| assessment of need and | | | | | |
| qualification for SUD | | | | | |
| services? If so, please | | | | | |
| describe these changes. | | | | | |
| ☑ The state has no implementation update to report for this reporting topic. | | | | | |
| 2.2 Access to Critical Levels of Care for OUD and other SUDs (Milestone 1) | | | | | |
| 2.2.1 Metric Trends | | | | | |

| Discuss any relevant trends | | | |
|---|---------------------|---|--|
| that the data shows related | | | |
| to assessment of need and qualification for SUD | | | |
| services. At a minimum, | | | |
| changes (+ or -) greater | | | |
| than two percent should be | | | |
| described. | | | |
| | DY20 Q3 | 6 Any SUD Treatment (-0.3%) | |
| | DY20 Q3 | 7 Early intervention (+100.0%) | This is a small numbers issue. Last quarter there was one claim, this quarter there are two claims. Early intervention services are not billed separately; they are included in claims for office visits. |
| | DY20 Q3 | 8 Outpatient Services (+3.7%) | For this period, we may be seeing people who disengaged with services during the pandemic now coming back into treatment or those who increased substance use during the pandemic seeking care. |
| | DY20 Q3 | 9 IOP/Partial hospitalization services (-0.9%) | |
| | DY20 Q3 | 10 Residential and Inpatient Services (+9.4%) | This may be related to people finally coming back into services who disengaged/relapsed during COVID. |
| | DY20 Q3 | 11 Withdrawal Management (-3.7%) | This is likely a small numbers issue. It went from 108 in Q2 to 112 in Q3. |
| | DY20 Q3 | 12 MAT (-5.9%) | One of the larger OTP providers has had billing problems that were finally resolved in DY20 Q4, after this reporting quarter. Longer term, this measure has stabilized, and we expect it to either maintain or decrease. Vermont has very high rates of MAT with nearly 3% of the state population aged 18-64 receiving treatment each year. |
| | | | |
| \Box The state has no metrics t | rends to report for | r this reporting topic. | |

| 2.2.2 Implementation Update | |
|------------------------------|---|
| Compared to the | The Division of Substance Use Programs (DSU) is |
| demonstration design and | executing the work included in the implementation |
| operational details outlined | roadmap for the expanded eligibility group for people |
| the implementation plan, | with a SUD diagnosis (referred to as "SUD CIT" - |
| have there been any | Community Intervention and Treatment) and continues |
| changes or does the state | executing the work included in the implementation |
| expect to make any changes | roadmaps that would make recovery services and |
| to: | supports, and withdrawal management services |
| a. Planned activities to | Medicaid eligible. These projects are currently |
| improve access to SUD | scheduled for a 2025 implementation. |
| treatment services | |
| across the continuum of | |
| care for Medicaid | |
| beneficiaries (e.g. | |
| outpatient services, | |
| intensive outpatient | |
| services, medication | |
| assisted treatment, | |
| services in intensive | |
| residential and inpatient | |
| settings, medically | |
| supervised withdrawal | |
| management)? | |
| b. SUD benefit coverage | |
| under the Medicaid | |
| state plan or the | |
| Expenditure Authority, | |
| particularly for | |
| residential treatment, | |
| medically supervised | |
| withdrawal | |

| management, and | | | |
|---|------------------------|---|--|
| medication assisted | | | |
| treatment services | | | |
| provided to individuals | | | |
| in IMDs? | | | |
| Are there any other | | | • |
| anticipated program | | | |
| changes that may impact | | | |
| metrics related to access to | | | |
| critical levels of care for | | | |
| OUD and other SUDs? If | | | |
| so, please describe these | | | |
| changes. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no implement | ntation updates to rep | port for this reporting topic. | |
| 3.2 Use of Evidence-based, S | SUD-specific Patien | t Placement Criteria (Milestone 2) | |
| 3.2.1 Metric Trends | • | , | |
| Discuss any relevant trends | | | |
| that the data shows related | | | |
| to assessment of need and | | | |
| qualification for SUD | | | |
| services. Changes (+ or -) | | | |
| greater than two percent | | | |
| should be described. | | | |
| [Add rows as needed] | | | |
| ☐ The state is reporting metrics related to Milestone 2 but has no metrics trends to report for this reporting topic. | | | |
| ☑ The state is not reporting a | any metrics related to | this reporting topic. | |
| 3.2.2 Implementation Upda | te | | |
| Compared to the | | | The Substance Use Disorder Treatment Standards, |
| demonstration design and | | | revised January 1, 2024, are being used to certify |
| operational details outlined | | | Preferred Providers and is available at: |

| the implementation plan, | https://www.healthvermont.gov/alcohol- |
|----------------------------|---|
| have there been any | drugs/professionals/treatment-provider-certification |
| changes or does the state | |
| expect to make any changes | The Compliance Assessment Tool (CAT) is used during |
| to: | site visits to determine a Preferred Provider's level of |
| a. Planned activities to | certification compliance by providing transparency |
| improve providers' use | about the Preferred Provider's status; highlighting areas |
| of evidence-based, | that require action or emphasis; and evaluating the level |
| SUD-specific | and type of technical assistance need. The CAT has |
| placement criteria? | been used two times between July 1, 2024, and |
| b. Implementation of a | September 30, 2024, at treatment provider locations. |
| utilization management | |
| approach to ensure: | |
| i. Beneficiaries | |
| have access to | |
| SUD services at | |
| the appropriate | |
| level of care? | |
| ii. Interventions are | |
| appropriate for | |
| the diagnosis and | |
| level of care? | |
| iii. Use of | |
| independent | |
| process for | |
| reviewing | |
| placement in | |
| residential | |
| treatment | |
| settings? | |
| Are there any other | |
| anticipated program | |

| changes that may impact | | | |
|--------------------------------------|------------------------|--|--|
| metrics related to the use of | | | |
| evidence-based, SUD- | | | |
| specific patient placement | | | |
| criteria (if the state is | | | |
| reporting such metrics)? If | | | |
| so, please describe these | | | |
| changes. | | | |
| \square The state has no implement | itation updates to rep | oort for this reporting topic. | |
| 4.2 Use of Nationally Recogn | nized SUD-specific | Program Standards to Set Provider (| Qualifications for Residential Treatment Facilities |
| (Milestone 3) | | _ | |
| 4.2.1 Metric Trends | | | |
| Discuss any relevant trends | | | |
| that the data shows related | | | |
| to assessment of need and | | | |
| qualification for SUD | | | |
| services. Changes (+ or -) | | | |
| greater than two percent | | | |
| should be described. | | | |
| [Add rows as needed] | | | |
| ☐ The state is reporting metri | ics related to Milesto | one 3 but has no metrics trends to report | t for this reporting topic. |
| ☑ The state is not reporting a | iny metrics related to | this reporting topic. | |
| 4.2.2 Implementation Update | te | | |
| Compared to the | | | The Substance Use Disorder Treatment Standards, |
| demonstration design and | | | revised January 1, 2024, are being used to certify |
| operational details outlined | | | Preferred Providers and is available at: |
| the implementation plan, | | | https://www.healthvermont.gov/alcohol- |
| have there been any | | | drugs/professionals/treatment-provider-certification |
| changes or does the state | | | |
| expect to make any changes | | | The Compliance Assessment Tool (CAT) is used during |
| to: | | | site visits to determine a Preferred Provider's level of |

| a. Implementation of residential treatment provider qualifications that meet the ASAM Criteria or other nationally recognized, | certification compliance by providing transparency about the Preferred Provider's status; highlighting areas that require action or emphasis; and evaluating the level and type of technical assistance need. The CAT has been used two times between July 1, 2024, and September 30, 2024, at treatment provider locations. |
|--|--|
| SUD-specific program standards? | |
| b. State review process for | |
| residential treatment | |
| providers' compliance | |
| with qualifications standards? | |
| c. Availability of | |
| medication assisted | |
| treatment at residential | |
| treatment facilities, either on-site or | |
| through facilitated | |
| access to services off | |
| site? | |
| Are there any other | |
| anticipated program | |
| changes that may impact metrics related to the use of | |
| nationally recognized SUD- | |
| specific program standards | |
| to set provider | |
| qualifications for residential | |
| treatment facilities (if the | |
| state is reporting such | |

| metrics)? If so, please | | | |
|--|------------------------|---|---|
| describe these changes. [Add rows as needed] | | | |
| ☐ The state has no implement | ntation undates to rer | port for this reporting topic. | |
| | | 1 0 1 | Assisted Treatment for OUD (Milestone 4) |
| 5.2.1 Metric Trends | | 9 | , , |
| Discuss any relevant trends | | | |
| that the data shows related | | | |
| to assessment of need and | | | |
| qualification for SUD | | | |
| services. At a minimum, | | | |
| changes (+ or -) greater than two percent should be | | | |
| described. | | | |
| [Add rows as needed] | DY20 Q3 Annual | 18 Percentage of beneficiaries aged 18 and older who received prescriptions for opioids with an average daily dosage greater than or equal to 90 morphine milligram equivalents (MME) over a period of 90 days or more. Beneficiaries with a cancer diagnosis, sickle cell disease diagnosis, or in hospice are excluded. (+11.6%) | There was a significant change in denominator - fewer people are receiving opioids – it went from 1342 in 2022 to 1194 in 2023. The number of beneficiaries receiving the 90+ MME for 90 days stayed the same 145 to 144. |
| | DY20 Q3 Annual | 21 Percentage of beneficiaries age 18 and older with concurrent use of prescription opioids and benzodiazepines. Beneficiaries with a cancer diagnosis, sickle cell disease diagnosis, or in hospice are excluded. (+4.8%) | The denominator for this measure decreased from 1884 to 1725. The numerator also decreased from 224 to 214 so fewer beneficiaries are receiving concurrent opioids and benzodiazepines. |

| ☑ The state has no metrics trends to report for this reporting topic. | | | |
|---|--------------------|--------------------------------------|---|
| 5.2.2 Implementation Update | te | | |
| Compared to the | | | |
| demonstration design and | | | |
| operational details outlined | | | |
| the implementation plan, | | | |
| have there been any | | | |
| changes or does the state | | | |
| expect to make any changes | | | |
| to planned activities to | | | |
| assess the availability of | | | |
| providers enrolled in | | | |
| Medicaid and accepting | | | |
| new patients in across the | | | |
| continuum of SUD care? | | | |
| Are there any other | | | |
| anticipated program | | | |
| changes that may impact | | | |
| metrics related to provider | | | |
| capacity at critical levels of | | | |
| care, including for | | | |
| medication assisted | | | |
| treatment (MAT) for OUD? | | | |
| If so, please describe these | | | |
| changes. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no implementation updates to report for this reporting topic. | | | |
| | prehensive Treatme | ent and Prevention Strategies to Add | ress Opioid Abuse and OUD (Milestone 5) |
| 6.2.1 Metric Trends | | | |
| Discuss any relevant trends | | | |
| that the data shows related | | | |
| to assessment of need and | | | |

| qualification for SUD services. At a minimum, changes (+ or -) greater than two percent should be described. | | | |
|--|----------------|---|--|
| | DY20 Q3 | 23 Emergency Department for SUD per 1000 beneficiaries (-3.1%) | The reason for this change is unclear. This measure may be responsive to the drug supply which may result in higher rates when the supply contains significant xylazine and decrease when it doesn't. Vermont distributes significant amounts of free naloxone to communities through SSPs, first responders, vending machines, mail order, etc. Vermont has also begun piloting methadone induction for individuals with SUD in need of MOUD with defined clinical pathways to community Hubs for continuity of care. As the pilot continues, we may see some community members accessing the ED for this purpose as an expansion of the rapid access to MOUD (RAM) initiative. |
| | DY20 Q3 | 24 Inpatient stays for SUD per 1000 (+4.6%) | This went from 562 in Q2 to 588 in Q3, a change of 26, with significant month to month variation. This may be related to the drug supply and associated wound care/infections. |
| | DY20 Q3 Annual | 15 Initiation of AOD Treatment - Total AOD abuse of dependence (- 0.9%) | Please note that these has been a change in the calculation methodology. The measure is defined in terms of HEDIS specs, but we generate our own figures to account for our Hub and Spoke program. There were significant updates to the HEDIS specs last year that didn't get reflected in our methodology. The 2022 data was rerun for direct comparison to 2023. |
| | DY20 Q3 Annual | 16 Engagement of AOD Treatment - Total AOD abuse of Dependence (+20.0%) | The change is related to increases in engagement for AUD and other drug use disorders. Engagement for OUD increased by 1%. Please note that these has been |

| | DY20 Q3 Annual | 17(1) Percentage of emergency department (ED) visits for beneficiaries age 18 and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence who had a follow-up visit for AOD abuse or dependence. Within 30 days (-8.1%) Within 7 days (-16.3%) | a change in the calculation methodology. The measure is defined in terms of HEDIS specs, but we generate our own figures to account for our Hub and Spoke program. There were significant updates to the HEDIS specs last year that didn't get reflected in our methodology. The 2022 data was rerun for direct comparison to 2023. In the past, we've submitted this as the HEDIS population matched against our SUD population, much like measure 32 (AAP). However, in reading over the specs, we noticed that measure 17(1) is described as the raw HEDIS measure, without matching it against the SUD population. For comparison, the measure 32 specs are very clear about matching against the SUD population. The 2022 data was rerun for direct comparison to 2023. |
|---|------------------------|---|---|
| | | | |
| ☐ The state has no metrics tr | ends to report for thi | s reporting topic. | |
| 6.2.2 Implementation Update | te | | |
| Compared to the demonstration design and operational details outlined the implementation plan, have there been any changes or does the state expect to make any changes to: a. Implementation of opioid prescribing guidelines and other | | | There are no planned changes to the prescribing guidelines and other interventions. |

| | | T | |
|---|---------------------|--------------------------------------|------|
| interventions related to | | | |
| prevention of OUD? | | | |
| b. Expansion of coverage | | | |
| for and access to | | | |
| naloxone? | | | |
| Are there any other | | | |
| anticipated program | | | |
| changes that may impact | | | |
| metrics related to the | | | |
| implementation of | | | |
| comprehensive treatment | | | |
| and prevention strategies to | | | |
| address opioid abuse and | | | |
| OUD? If so, please describe | | | |
| these changes. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no implement | | | |
| 7.2 Improved Care Coordina | ation and Transitio | ons between Levels of Care (Mileston | e 6) |
| 7.2.1 Metric Trends | | | |
| Discuss any relevant trends | | | |
| that the data shows related | | | |
| to assessment of need and | | | |
| qualification for SUD | | | |
| services. At a minimum, | | | |
| changes (+ or -) greater | | | |
| than two percent should be | | | |
| described. | | | |
| | | | |
| ☑ The state has no metrics trends to report for this reporting topic. | | | |
| 7.2.2 Implementation Update | e | | |

| Compared to the demonstration design and operational details outlined the implementation plan, have there been any changes or does the state expect to make any changes to implementation of policies supporting beneficiaries' transition from residential and inpatient facilities to community-based services and supports? Are there any other anticipated program | | Vermont has utilized some opioid settlement dollars to support outreach and engagement activities within the |
|---|------------------|--|
| changes that may impact metrics related to care | | residential programs. This is intended to support individuals following through with entering residential |
| coordination and transitions | | treatment and engagement with outpatient or other |
| between levels of care? If | | stepdown treatment services after discharge. |
| so, please describe these | | |
| changes. | | |
| [Add rows as needed] | | |
| ☑ The state has no implementation up | 1 1 | opic. |
| 8.2 SUD Health Information Techno | logy (Health IT) | |
| 8.2.1 Metric Trends | | |
| Discuss any relevant trends | | |
| that the data shows related | | |
| to assessment of need and | | |
| qualification for SUD | | |
| services. Changes (+ or -) | | |

| greater than two percent | |
|--|---|
| should be described. | |
| [Add rows as needed] | |
| ☐ The state has no metrics trends to report for this reporting | ng topic. |
| 8.2.2 Implementation Update | |
| Compared to the | VPMS integrated with two healthcare practice sites, one |
| demonstration design and | of which is a SUD clinic. The program reviewed the |
| operational details outlined | connections with New York, Maryland, Kentucky and |
| in STCs and | Colorado and increased sharing through RxCheck. |
| implementation plan, have | |
| there been any changes or | A process to streamline onboarding of practices was |
| does the state expect to | developed including an integration FAQ document and a |
| make any changes to: | formalization of health care entity contacts sheet, which |
| a. How health IT is being | will standardize the process through which health care |
| used to slow down the | organizations can be queued for integration. |
| rate of growth of | |
| individuals identified | Vermont's assembled Part 2 Data Governance Group |
| with SUD? | has successfully incorporated SUD data into the |
| b. How health IT is being | Vermont Health Information Exchange (VHIE) for a |
| used to treat effectively | select group of providers. The data is going into a |
| individuals identified | repository but is not yet accessible for use. Other SUD |
| with SUD? | providers will be included over time, although a timeline |
| c. How health IT is being | has not yet been established. |
| used to effectively | Vermont's health information exchange, data |
| monitor "recovery" | governance information and documents, including those |
| supports and services | for 42 CFR Part 2, are available at: |
| for individuals | https://healthdata.vermont.gov/vermont-health- |
| identified with SUD? | information-exchange-data-governance |
| d. Other aspects of the | |
| state's plan to develop | |
| the health IT | |
| infrastructure/capabiliti | |

| | | - | · |
|-------------------------------|------------------------|--------------------------------|---|
| es at the state, delivery | | | |
| system, health | | | |
| plan/MCO, and | | | |
| individual provider | | | |
| levels? | | | |
| e. Other aspects of the | | | |
| state's health IT | | | |
| implementation | | | |
| milestones? | | | |
| f. The timeline for | | | |
| achieving health IT | | | |
| implementation | | | |
| milestones? | | | |
| g. Planned activities to | | | |
| increase use and | | | |
| functionality of the | | | |
| state's prescription | | | |
| drug monitoring | | | |
| program? | | | |
| Are there any other | | | |
| anticipated program | | | |
| changes that may impact | | | |
| metrics related to SUD | | | |
| Health IT (if the state is | | | |
| reporting such metrics)? If | | | |
| so, please describe these | | | |
| changes. | | | |
| | | | |
| | | | |
| ☐ The state has no implemen | itation updates to rep | oort for this reporting topic. | |
| 9.2 Other SUD-Related Metrics | | | |
| 9.2.1 Metric Trends | | | |

| | | <u>, </u> |
|------------------------|-------------------------------|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| DY20 Q3 Annual | | |
| | | |
| | | |
| | | |
| | (+1.5%) | |
| | | |
| | | |
| | | |
| nds to report for this | s reporting topic. | |
| e | | |
| | | • |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| ation updates to rep | ort for this reporting topic. | |
| • | <u> </u> | |
| alysis | | |
| • | | Updates on Budget Neutrality can be found in Section |
| | | V. Financial/Budget Neutrality Development/Issues |
| | | |
| | ation updates to rep | beneficiaries with SUD who had an ambulatory or preventive care visit during the measurement period. (+1.5%) ands to report for this reporting topic. |

| budget neutrality to date. If | |
|---|--|
| the SUD component is part | |
| of a comprehensive | |
| demonstration, the state | |
| should provide an analysis | |
| of the SUD-related budget | |
| neutrality and an analysis of | |
| budget neutrality as a | |
| whole. | |
| [Add rows as needed] | |
| ☐ The state has no metrics trends to report for thi | reporting topic. |
| 10.2.2 Implementation Update | |
| are there any anticipated | |
| program changes that may | |
| impact budget neutrality? If | |
| so, please describe these | |
| changes. | |
| [Add rows as needed] | |
| ☑ The state has no implementation updates to rep | ort for this reporting topic. |
| 11.1 SUD-Related Demonstration Operations a | d Policy |
| 11.1.1 Considerations | |
| Highlight significant SUD | The Division of Substance Use Programs (DSU) is |
| (or if broader | executing the work included in the implementation |
| demonstration, then SUD- | roadmap for the expanded eligibility group for people |
| related) demonstration | with a SUD diagnosis (referred to as "SUD CIT" - |
| operations or policy | Community Intervention and Treatment) and continues |
| considerations that could | to execute the work included in the implementation |
| positively or negatively | roadmaps that make recovery services and supports, and |
| impact beneficiary | withdrawal management services Medicaid eligible. |
| enrollment, access to | These projects are currently scheduled for 2025 |
| services, timely provision | implementation. |
| of services, budget | |

| . 12 | | | |
|-------------------------------------|---------------------|-----------------------------|--|
| neutrality, or any other | | | |
| provision that has potential | | | |
| for beneficiary impacts. | | | |
| Also note any activity that | | | |
| may accelerate or create | | | |
| delays or impediments in | | | |
| achieving the SUD | | | |
| demonstration's approved | | | |
| goals or objectives, if not | | | |
| already reported elsewhere | | | |
| in this document. See report | | | |
| template instructions for | | | |
| more detail. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no related consider | iderations to repor | t for this reporting topic. | |
| 11.1.2 Implementation Update | , | | |
| Compared to the | | | |
| demonstration design and | | | |
| operational details outlined | | | |
| in STCs and the | | | |
| implementation plan, have | | | |
| there been any changes or | | | |
| does the state expect to | | | |
| make any changes to: | | | |
| a. How the delivery | | | |
| system operates under | | | |
| the demonstration (e.g. | | | |
| through the managed | | | |
| care system or fee for | | | |
| service)? | | | |
| b. Delivery models | | | |
| affecting demonstration | | | |

12.1 SUD Demonstration Evaluation Update

12.1.1 Narrative Information

| participants (e.g. Accountable Care Organizations, Patient Centered Medical Homes)? c. Partners involved in service delivery? Has the state experienced any significant challenges in participants (e.g. Accountable Care Organizations, Patient Centered Medical Homes)? |
|--|
| Organizations, Patient Centered Medical Homes)? c. Partners involved in service delivery? Has the state experienced any significant challenges |
| Centered Medical Homes)? c. Partners involved in service delivery? Has the state experienced any significant challenges |
| Homes)? c. Partners involved in service delivery? Has the state experienced any significant challenges |
| c. Partners involved in service delivery? Has the state experienced any significant challenges |
| service delivery? Has the state experienced any significant challenges |
| Has the state experienced any significant challenges |
| any significant challenges |
| |
| in month only a south and this a |
| in partnering with entities |
| contracted to help |
| implement the |
| demonstration (e.g., health |
| plans, credentialing |
| vendors, private sector |
| providers)? Has the state |
| noted any performance |
| issues with contracted |
| entities? |
| What other initiatives is the |
| state working on related to |
| SUD or OUD? How do |
| these initiatives relate to the |
| SUD demonstration? How |
| are they similar to or |
| different from the SUD |
| demonstration? |
| [Add rows as needed] |
| ☐ The state has no implementation updates to report for this reporting topic. |

| Provide updates on SUD | | | Updates on the SUD evaluation work, deliverables and |
|---|-----------------------|---|--|
| evaluation work and | | | timeline can be found in Sections VIII. Quality |
| timeline. The appropriate | | | Improvement and IX. Demonstration Evaluation of the |
| content will depend on | | | Broad Demonstration Monitoring Report. |
| when this report is due to | | | Broad Demonstration Womtoring Report. |
| CMS and the timing for the | | | |
| | | | |
| demonstration. See report | | | |
| template instructions for more details. | | | |
| | | | |
| Provide status updates on deliverables related to the | | | |
| | | | |
| demonstration evaluation | | | |
| and indicate whether the | | | |
| expected timelines are | | | |
| being met and/or if there | | | |
| are any real or anticipated | | | |
| barriers in achieving the | | | |
| goals and timeframes | | | |
| agreed to in the STCs. | | | |
| List anticipated evaluation- | | | |
| related deliverables related | | | |
| to this demonstration and | | | |
| their due dates. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no SUD demo | onstration evaluation | update to report for this reporting top | nic. |
| 13.1 Other Demonstration Re | | | |
| 13.1.1 General Reporting Rec | quirements | | |
| Have there been any | | | |
| changes in the state's | | | |
| implementation of the | | | |
| demonstration that might | | | |
| necessitate a change to | | | |

| | 1 | | |
|------------------------------|---|---|--|
| approved STCs, | | | |
| implementation plan, or | | | |
| monitoring protocol? | | | |
| Does the state foresee the | | | |
| need to make future | | | |
| changes to the STCs, | | | |
| implementation plan, or | | | |
| monitoring protocol, based | | | |
| on expected or upcoming | | | |
| implementation changes? | | | |
| Compared to the details | | _ | Updates on the Monitoring Protocol work, deliverables, |
| outlined in the STCs and | | | and timeline can be found in Section X. Compliance of |
| the monitoring protocol, | | | the Broad Demonstration Monitoring Report. |
| has the state formally | | | |
| requested any changes or | | | |
| does the state expect to | | | |
| formally request any | | | |
| changes to: | | | |
| a. The schedule for | | | |
| completing and | | | |
| submitting monitoring | | | |
| reports? | | | |
| b. The content or | | | |
| completeness of | | | |
| submitted reports? | | | |
| Future reports? | | | |
| Has the state identified any | | | |
| real or anticipated issues | | | |
| submitting timely post- | | | |
| approval demonstration | | | |
| deliverables, including a | | | |
| plan for remediation? | | | |

| [Add rows as needed] | | | | |
|--|---------------------|--------|--|--|
| ☐ The state has no updates on general reporting requirements to report for this reporting topic. | | | | |
| 13.1.2 Post Award Public Fo | orum | | | |
| If applicable within the | | | | |
| timing of the | | | | |
| demonstration, provide a | | | | |
| summary of the annual | | | | |
| post-award public forum | | | | |
| held pursuant to 42 CFR § | | | | |
| 431.420(c) indicating any | | | | |
| resulting action items or | | | | |
| issues. A summary of the | | | | |
| post-award public forum | | | | |
| must be included here for | | | | |
| the period during which the | | | | |
| forum was held and in the | | | | |
| annual report. | | | | |
| [Add rows as needed] | | | | |
| - | | | not an annual report, so the state has no post award | |
| public forum update to report | | | | |
| 14.1 Notable State Achieven | nents and/or Innova | ations | | |
| 14.1 Narrative Information | | | | |
| Provide any relevant | | | | |
| summary of achievements | | | | |
| and/or innovations in | | | | |
| demonstration enrollment, | | | | |
| benefits, operations, and | | | | |
| policies pursuant to the | | | | |
| hypotheses of the SUD (or | | | | |
| if broader demonstration, | | | | |
| then SUD related) | | | | |
| demonstration or that | | | | |

| served to provide better | | | |
|--|--|--|--|
| care for individuals, better | | | |
| health for populations, | | | |
| and/or reduce per capita | | | |
| cost. Achievements should | | | |
| focus on significant impacts | | | |
| to beneficiary outcomes. | | | |
| Whenever possible, the | | | |
| summary should describe | | | |
| the achievement or | | | |
| innovation in quantifiable | | | |
| terms, e.g., number of | | | |
| impacted beneficiaries. | | | |
| [Add rows as needed] | | | |
| ☐ The state has no notable achievements or innovations to report for this reporting topic. | | | |